P2318
Anti-Pseudomonas Exotoxin A antibody produced in rabbit
whole antiserum
Synonym(s):
Anti-ETA
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
rabbit
conjugate
unconjugated
antibody form
whole antiserum
antibody product type
primary antibodies
clone
polyclonal
contains
15 mM sodium azide
species reactivity
(Pseudomonas aeruginosa)
technique(s)
dot blot: 1:20,000
indirect ELISA: 1:250,000
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
Pseudomonas aeruginosa PAO1 ... toxA(877850)
General description
Reacts against Pseudomonas exotoxin A, but shows no reaction against Staphylococcal enterotoxin A, Cholera toxin, and Staphylococcal enterotoxin B. The product has not been tested for neutralization potency against active Pseudomonas exotoxin A.
Immunogen
exotoxin A from Pseudomonas aeruginosa.
Application
Anti-Pseudomonas Exotoxin A antibody has been used in in vitro serum stability of fusion toxins and binding of targeted toxins.
Anti-Pseudomonas exotoxin A antibody produced in rabbit has been used:
- in the in vitro analysis of the stability of fusion toxins in serum
- to construct an epidermal growth factor receptor (EGFR)-targeted toxin to study its toxicity on Swiss mouse embryo NIH-3T3 cells transfected with human EGFR
- in the determination of the in vivo half-life of immunotoxins in serum
Biochem/physiol Actions
Pseudomonas exotoxin A is secreted by Pseudomonas aeruginosa and has potent cytotoxic effects. Exotoxin A enters the cells by receptor-mediated endocytosis, translocates to the cytoplasm and inhibits protein synthesis by ADP-ribosylating factor 2. Chimeric exotoxin A has applications in gene treatment of various diseases and probable treatment for cancer.
Physical form
This product is supplied as a liquid containing 15 mM sodium azide as preservative.
Storage and Stability
For continuous use, store at 2-8 °C for up to one month. For extended storage, the solution may be frozen in working aliquots. Repeated freezing and thawing is not recommended. Storage in "frost-free" freezers is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Alexander N Wein et al.
Journal of medicinal chemistry, 55(18), 7998-8006 (2012-09-08)
Protective antigen (PA), lethal factor, and edema factor, the protein toxins of Bacillus anthracis , are among its most important virulence factors and play a key role in infection. We performed a virtual ligand screen of a library of 10000
Moritz Bewarder et al.
Cancer immunology, immunotherapy : CII, 69(8), 1535-1548 (2020-04-18)
With an infection rate of 60-90%, the human cytomegalovirus (HCMV) is very common among adults but normally causes no symptoms. When T cell-mediated immunity is compromised, HCMV reactivation can lead to increased morbidity and mortality. HCMV antigens are processed and
Alexander Weng et al.
Molecular oncology, 6(3), 323-332 (2012-02-09)
Tumor-targeting protein toxins are composed of a toxic enzyme coupled to a specific cell binding domain that targets cancer-associated antigens. The anti-tumor treatment by targeted toxins is accompanied by dose-limiting side effects. The future prospects of targeted toxins for therapeutic
Fusion of an albumin-binding domain extends the half-life of immunotoxins
Guo R, et al.
International Journal of Pharmaceutics, 511(1), 538-549 (2016)
Nihal Karakaş et al.
International journal of molecular medicine, 48(1) (2021-06-04)
Glioblastomas (GBMs) are refractory to current treatments and novel therapeutic approaches need to be explored. Pro‑apoptotic tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) is tumor‑specific and has been shown to induce apoptosis and subsequently kill GBM cells. However, approximately 50% of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service